Barinthus Biotherapeutics (BRNS) Competitors $1.10 -0.05 (-4.34%) Closing price 04:00 PM EasternExtended Trading$1.10 +0.00 (+0.45%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BRNS vs. TIL, MDWD, AARD, ENTA, TVGN, CGTX, BIOA, DERM, ACTU, and FTLFShould you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include Instil Bio (TIL), MediWound (MDWD), Aardvark Therapeutics (AARD), Enanta Pharmaceuticals (ENTA), Tevogen Bio (TVGN), Cognition Therapeutics (CGTX), BioAge Labs (BIOA), Journey Medical (DERM), Actuate Therapeutics (ACTU), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry. Barinthus Biotherapeutics vs. Its Competitors Instil Bio MediWound Aardvark Therapeutics Enanta Pharmaceuticals Tevogen Bio Cognition Therapeutics BioAge Labs Journey Medical Actuate Therapeutics FitLife Brands Instil Bio (NASDAQ:TIL) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment. Do insiders and institutionals hold more shares of TIL or BRNS? 60.6% of Instil Bio shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 46.5% of Instil Bio shares are held by company insiders. Comparatively, 8.0% of Barinthus Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media refer more to TIL or BRNS? In the previous week, Instil Bio had 4 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 4 mentions for Instil Bio and 0 mentions for Barinthus Biotherapeutics. Instil Bio's average media sentiment score of 0.00 equaled Barinthus Biotherapeutics'average media sentiment score. Company Overall Sentiment Instil Bio Neutral Barinthus Biotherapeutics Neutral Which has more risk & volatility, TIL or BRNS? Instil Bio has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Comparatively, Barinthus Biotherapeutics has a beta of -0.75, indicating that its stock price is 175% less volatile than the S&P 500. Do analysts prefer TIL or BRNS? Instil Bio presently has a consensus price target of $119.00, suggesting a potential upside of 417.84%. Barinthus Biotherapeutics has a consensus price target of $3.00, suggesting a potential upside of 172.73%. Given Instil Bio's higher probable upside, analysts clearly believe Instil Bio is more favorable than Barinthus Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00Barinthus Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings and valuation, TIL or BRNS? Barinthus Biotherapeutics has higher revenue and earnings than Instil Bio. Instil Bio is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInstil BioN/AN/A-$74.14M-$12.92-1.78Barinthus Biotherapeutics$14.97M2.99-$61.07M-$1.73-0.64 Is TIL or BRNS more profitable? Instil Bio's return on equity of -54.32% beat Barinthus Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Instil BioN/A -54.32% -33.65% Barinthus Biotherapeutics N/A -54.70%-44.75% SummaryInstil Bio beats Barinthus Biotherapeutics on 9 of the 13 factors compared between the two stocks. Get Barinthus Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BRNS vs. The Competition Export to ExcelMetricBarinthus BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.79M$3.15B$5.78B$10.04BDividend YieldN/A2.28%5.27%4.52%P/E Ratio-0.6421.4475.5026.08Price / Sales2.99428.01516.52171.73Price / CashN/A45.5837.2059.76Price / Book0.349.6011.536.20Net Income-$61.07M-$53.33M$3.29B$270.65M7 Day Performance-13.39%0.61%0.44%2.70%1 Month Performance-17.91%11.11%10.84%8.77%1 Year Performance-11.29%12.61%61.62%27.39% Barinthus Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BRNSBarinthus Biotherapeutics2.3868 of 5 stars$1.10-4.3%$3.00+172.7%-10.2%$44.79M$14.97M-0.64107Positive NewsGap DownTILInstil Bio3.1792 of 5 stars$29.22+8.2%$119.00+307.3%+15.9%$182.27MN/A-2.26410News CoverageGap UpMDWDMediWound1.5267 of 5 stars$16.60-0.6%$32.25+94.3%-3.0%$180.49M$20.22M-6.2980Gap UpAARDAardvark TherapeuticsN/A$8.86+6.7%$32.60+267.9%N/A$180.08MN/A0.0018News CoverageHigh Trading VolumeENTAEnanta Pharmaceuticals3.8453 of 5 stars$9.00+7.1%$22.25+147.2%-22.3%$179.57M$67.64M-2.08160Positive NewsHigh Trading VolumeTVGNTevogen Bio3.3817 of 5 stars$0.89-2.2%$10.00+1,023.6%+111.3%$179MN/A0.003CGTXCognition Therapeutics1.9747 of 5 stars$2.43flat$2.83+16.6%+318.5%$178.66MN/A-3.6320BIOABioAge LabsN/A$4.65-5.7%N/AN/A$176.74MN/A0.00N/APositive NewsHigh Trading VolumeDERMJourney Medical1.8737 of 5 stars$7.12-1.2%$12.17+70.9%+54.2%$175.77M$56.13M-18.7490ACTUActuate Therapeutics2.0231 of 5 stars$8.70+3.1%$20.33+133.7%+2.9%$175.09MN/A0.0010News CoverageGap DownFTLFFitLife Brands3.6446 of 5 stars$18.05-3.1%$22.00+21.9%+14.5%$174.86M$64.47M21.4920Positive News Related Companies and Tools Related Companies TIL Competitors MDWD Competitors AARD Competitors ENTA Competitors TVGN Competitors CGTX Competitors BIOA Competitors DERM Competitors ACTU Competitors FTLF Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BRNS) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredWall Street legend: “Put $1,000 in this AI stock”A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredTrump’s reported death a hoaxHow Trump’s latest policies could trigger a full-scale debt collapse… And the specific investments that cou...Porter & Company | SponsoredLitecoin’s Creator Backs the World’s First TreasuryBitcoin's corporate adoption story has been written. Litecoin's is just beginning.The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
